Recombinant monoclonal antibody to CD22. Manufactured using Recombinant Platform with variable regions (i.e. specificity) from the hybridoma hL22 (Epratuzumab).
應用類型
抗CD22（依普妥珠單抗），人類IgG1抗體Anti-CD22 (Epratuzumab), Human IgG1 Antibody該產品的應用類型查閱產品說明書。
免疫原
This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5–10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).
來源宿主
提供的抗CD22（依普妥珠單抗），人類IgG1抗體Anti-CD22 (Epratuzumab), Human IgG1 Antibody產品，該來源宿主查看產品說明書。
